Proton beam therapy for renal pelvis and ureter cancer: A report of 5 cases and a literature review

Iizumi,Takashi; Ishikawa,Hitoshi; Sekino,Yuta; Ohnishi,Kayoko; Mizumoto,Masashi; Nonaka,Tetsuo; Sakurai,Hideyuki

doi:10.3892/mco.2019.1861

Proton beam therapy for renal pelvis and ureter cancer: A report of 5 cases and a literature review

Authors:
- Takashi Iizumi
- Hitoshi Ishikawa
- Yuta Sekino
- Kayoko Ohnishi
- Masashi Mizumoto
- Tetsuo Nonaka
- Hideyuki Sakurai
View Affiliations

Affiliations: Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, Faculty of Medicine, Tsukuba, Ibaraki 305‑8576, Japan
Published online on: May 20, 2019 https://doi.org/10.3892/mco.2019.1861
Pages: 24-30

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Standard treatment for localized renal pelvis and ureter cancer is surgery. Previously, the primary role of radiation therapy (RT) in cancer treatment was to control pain and hemostasis as palliative or as adjuvant therapy following surgery. In this report, we describe 5 patients with the disease treated with proton beam therapy (PBT) as curative treatment. Between September 2009 and July 2013, 5 males with renal pelvis (n=3) or ureter (n=2) cancer were treated by PBT with hypofractionated [72.6 Gy relative biological effectiveness (RBE)/22 fractions] or conventional [64‑66 Gy (RBE)/32‑33 fractions] fractionation. The median patient age was 72 years (range, 59‑85 years). Three patients were deemed unfit for surgery. Local hypofractionated PBT was performed in 2 patients with T1‑2N0M0 diseases, while prophylactic lymph node irradiation using a patch irradiation technique was performed for the remaining 3 patients, who had T3‑4 disease. Two patients with T3‑4 disease received chemotherapy prior to definitive PBT. No serious acute or late toxicities were observed in any patient. Local tumor control was achieved in 3 patients (60%); however, distant metastases were observed in 2 patients. Four of the five patients (80%) evaluated in the present study survived for >3 years. The data is limited; however, PBT appears to be a potential option for patients with renal pelvis or ureter cancer, especially for those who are unsuitable for radical surgery.

View Figures

View References

1	Kirkali Z and Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 47:155–169. 2003. View Article : Google Scholar : PubMed/NCBI
2	Huben RP, Mounzer AM and Murphy GP: Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 62:2016–2020. 1988. View Article : Google Scholar : PubMed/NCBI
3	Hutchinson R, Haddad A, Saqalowsky A and Margulis V: Upper tract urothelial carcinoma: Special considerations. Clin Adv Hematol Oncol. 14:101–109. 2016.PubMed/NCBI
4	Soderdahl DW, Fabrizio MD, Rahman NU, Jarrett TW and Bagley DH: Endoscopic treatment of upper tract transitional cell carcinoma. Urol Oncol. 23:114–122. 2005. View Article : Google Scholar : PubMed/NCBI
5	Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S and Raymond R: Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int J Radiat Oncol Biol Phys. 24:743–745. 1992. View Article : Google Scholar : PubMed/NCBI
6	Czito B, Zietman A, Kaufman D, Skowronski U and Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 172:1271–1275. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ding T, Zheng Z, Xu R and Zhou C: Prognostic factors and outcomes of primary transitional cell carcinoma of the ureter: A population-based study. Oncotarget. 8:65983–65996. 2017. View Article : Google Scholar : PubMed/NCBI
8	DeLaney TF, Trofimov AV, Engelsman M and Suit HD: Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control. 12:27–35. 2005. View Article : Google Scholar : PubMed/NCBI
9	Inada T, Hayakawa Y, Tada J, Takada Y and Maruhashi A: Characteristics of proton beams after field shaping at PMRC. Med Biol Eng Comput. 31 (Suppl):S44–S48. 1993. View Article : Google Scholar : PubMed/NCBI
10	Iwata H, Ishikawa H, Takagi M, Okimoto T, Murayama S, Akimoto T, Wada H, Arimura T, Sato Y, Araya M, et al: Long-term outcomes of proton therapy for prostate cancer in Japan: A multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med. 7:677–689. 2018. View Article : Google Scholar : PubMed/NCBI
11	Ha B, Cho KH, Lee KH, Joung JY, Kim YJ, Lee SU, Kim H, Suh YG, Moon SH, Lim YK, et al: Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: Moderate versus extreme hypofractionation. Radiat Oncol. 14:42019. View Article : Google Scholar : PubMed/NCBI
12	Verma V, Simone CB II and Mishra MV: Quality of life and patient-reported outcomes following proton radiation therapy: A systematic review. J Natl Cancer Inst. 110:2018. View Article : Google Scholar : PubMed/NCBI
13	Takaoka EI, Miyazaki J, Ishikawa H, Kawai K, Kimura T, Ishitsuka R, Kojima T, Kanuma R, Takizawa D, Okumura T, et al: Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer. Jpn J Clin Oncol. 47:67–73. 2017. View Article : Google Scholar : PubMed/NCBI
14	Hata M, Miyanaga N, Tokuuye K, Saida Y, Ohara K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Hattori K, et al: Proton beam therapy for invasive bladder cancer: A prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys. 64:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
15	Maehata Y, Kuriyama K, Aoki S, Araya M, Marino K and Onishi H: Stereotactic body radiotherapy for localized ureter transitional cell carcinoma: Three case reports. Case Rep Urol. 2015:5198972015.PubMed/NCBI
16	Evans JD, Hansen CC, Tollefson MK and Hallemeier CL: Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report. Adv Radiat Oncol. 3:57–61. 2017. View Article : Google Scholar : PubMed/NCBI
17	Oshiro Y, Mizumoto M, Okumura T, Fukuda K, Fukumitsu N, Abei M, Ishikawa H, Takizawa D and Sakurai H: Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 123:240–245. 2017. View Article : Google Scholar : PubMed/NCBI
18	Okonogi N, Hashimoto T, Ishida M, Ohno T, Terunuma T, Okumura T, Sakae T and Sakurai H: Designed-seamless irradiation technique for extended whole mediastinal proton-beam irradiation for esophageal cancer. Radiat Oncol. 7:1732012. View Article : Google Scholar : PubMed/NCBI
19	Ishikawa H, Hashimoto T, Moriwaki T, Hyodo I, Hisakura K, Terashima H, Ohkohchi N, Ohno T, Makishima H, Mizumoto M, et al: Proton beam therapy combined with concurrent chemotherapy for esophageal cancer. Anticancer Res. 35:1757–1762. 2015.PubMed/NCBI
20	Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, et al: European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
21	Charbit L, Gendroau MC, Mee S and Cukier J: Tumors of the upper urinary tract: 10 years of experience. J Urol. 146:1243–1246. 1991. View Article : Google Scholar : PubMed/NCBI
22	Miyao N, Masumori N, Takahashi A, Sasai M, Hisataki T, Kitamura H, Satoh M and Tsukamoto T: Lymph nodde metastasis in patients with carcinomas of the renal pelvis and ureter. Eur Urol. 33:180–185. 1998. View Article : Google Scholar : PubMed/NCBI
23	Yang D, Chen Q, Song X, Wang J, Che X, Zhu Z, Zheng W and Wang L: Effect of lymph node dissection on the outcomes of upper tract urothelial carcinomas: A meta-analysis. Expert Rev Anticancer Ther. 14:667–675. 2014. View Article : Google Scholar : PubMed/NCBI